Oncopeptides
1.52
SEK
+1.2 %
ONCO
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 following
+1.2%
-29.79%
-30.91%
-43.81%
-72.16%
-75.26%
-74.46%
-98.33%
-95.04%
www.oncopeptides.com/en/investors
Oncopeptides is a biotech company that develops drugs for difficult-to-treat hematological diseases. The company uses its PDC platform to develop peptide-linked drugs that selectively deliver cytotoxic drugs into cancer cells. The company has drugs in commercialization and several drug candidates under development. Oncopeptide's head office is located in Stockholm.
Revenue
35.22M
EBIT %
-719.62 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
ONCO
Daily low / high price
1.5 / 1.52
SEK
Market cap
327.08M SEK
Turnover
7.67K SEK
Volume
5.1K
Latest videos
Financial calendar
Annual report
27.02.2025
Interim report
08.05.2025
General meeting
22.05.2025
Interim report
21.08.2025
Interim report
05.11.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| HealthCap VIII L.P. | 12.7 % | 12.9 % |
| HealthCap VI L.P. | 6.6 % | 6.7 % |
| Avanza Pension | 6.5 % | 6.6 % |
| Redmile Group LLC | 6.5 % | 6.6 % |
| Hans Edvin Öhman | 4.9 % | 4.9 % |
| Nordnet Pensionsförsäkring | 4.5 % | 4.6 % |
| Handelsbanken Fonder | 2.5 % | 2.5 % |
| Oncopeptides AB | 1.8 % | 0.2 % |
| Jakob Lindberg | 0.9 % | 0.9 % |
| Johan Zetterstedt | 0.7 % | 0.7 % |
ShowingAll content types
Oncopeptides invited to present data on PDC platform efficacy in Acute Myeloid Leukemia at the American Society of Hematology meeting
Redeye: Oncopeptides Q3 2024 - Sluggish Growth
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Oncopeptides, Audiocast with teleconference, Q3'24
Oncopeptides publishes Q3 report 2024
Oncopeptides AB: Oncopeptides will present at the BioStock Life Science Summit, November 20
Invitation to presentation of the Q3 report 2024
Oncopeptides signs license agreement with SCBIO for Pepaxti in South Korea
Redeye: Oncopeptides Q2 2024 - Strong Q/Q Sales Growth
Oncopeptides, Audiocast with teleconference, Q2'24
Oncopeptides publishes Q2 report 2024
Invitation to presentation of the Q2 report 2024
First patient enters Oncopeptides study aiming to gain real-world insights from Pepaxti in Germany
Number of shares and votes in Oncopeptides
Oncopeptides selects first candidate drug from its SPiKE platform
Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
Number of shares and votes in Oncopeptides
